About Bio-Reference Laboratories (NASDAQ:BRLI)
Bio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.
Industry, Sector and Symbol
Industry Medical & Diagnostic Laboratories
Sub-IndustryHealth Care Services
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity12.67%
Return on Assets8.38%
Bio-Reference Laboratories (NASDAQ:BRLI) Frequently Asked Questions
What is Bio-Reference Laboratories' stock symbol?
Bio-Reference Laboratories trades on the NASDAQ under the ticker symbol "BRLI."
How were Bio-Reference Laboratories' earnings last quarter?
Bio-Reference Laboratories Inc (NASDAQ:BRLI) posted its quarterly earnings data on Thursday, December, 18th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.03. The medical research company earned $227.60 million during the quarter, compared to analysts' expectations of $228.81 million. Bio-Reference Laboratories had a return on equity of 12.67% and a net margin of 4.67%. The firm's revenue for the quarter was up 18.4% on a year-over-year basis. During the same period last year, the firm earned $0.40 EPS. View Bio-Reference Laboratories' Earnings History.
Who are some of Bio-Reference Laboratories' key competitors?
Some companies that are related to Bio-Reference Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Roche (ROG), Merck & Co., Inc. (MRK), Sanofi (SAN), Bayer (BAYN), GlaxoSmithKline (GSK), CSL (CSL), Beximco Pharmaceuticals (BXP), Shire (SHP), Essilor International (EI), Ramsay Health Care (RHC), Medivation (MDVN), Catamaran (CTRX), Hologic (HOLX), Merck KGaA (MRK), Teleflex (TFX) and Henry Schein (HSIC).
How do I buy Bio-Reference Laboratories stock?
Shares of Bio-Reference Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Bio-Reference Laboratories?
Bio-Reference Laboratories' mailing address is 481 Edward H Ross Dr, ELMWOOD PARK, NJ 07407-3118, United States. The medical research company can be reached via phone at +1-201-7912186.
MarketBeat Community Rating for Bio-Reference Laboratories (BRLI)MarketBeat's community ratings are surveys of what our community members think about Bio-Reference Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bio-Reference Laboratories (NASDAQ:BRLI) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Bio-Reference Laboratories (NASDAQ:BRLI) Earnings History and Estimates Chart
Bio-Reference Laboratories (NASDAQ BRLI) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/8/2015||Q215||$0.46||$0.38||$227.33 million||$224.00 million||View||Listen|
|3/5/2015||Q115||$0.36||$0.24||$216.40 million||$209.00 million||View||Listen|
|12/18/2014||Q414||$0.63||$0.66||$228.81 million||$227.60 million||View||Listen|
|8/27/2014||Q314||$0.53||$0.55||$210.44 million||$222.10 million||View||Listen|
|6/5/2014||Q214||$0.32||$0.37||$0.20 million||$201.30 million||View||Listen|
|3/4/2014||Q114||$0.14||$0.11||$175.52 million||$181.30 million||View||Listen|
|12/19/2013||Q4||$0.40||$0.40||$188.96 million||$192.20 million||View||Listen|
|8/29/2013||Q3 2013||$0.51||$0.53||$183.50 million||$185.40 million||View||Listen|
|6/6/2013||Q2 2013||$0.41||$0.41||$176.04 million||$176.50 million||View||Listen|
|2/28/2013||Q1 2013||$0.28||$0.31||$165.44 million||$161.30 million||View||Listen|
|8/30/2012||Q312||$0.43||$0.45||$0.17 million||$0.17 million||View||N/A|
|12/16/2010||$0.30||$0.31||$124.19 million||$126.60 million||View||N/A|
Bio-Reference Laboratories (NASDAQ:BRLI) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Bio-Reference Laboratories (NASDAQ:BRLI)
No dividend announcements for this company have been tracked by MarketBeat.com
Bio-Reference Laboratories (NASDAQ BRLI) News Headlines
Bio-Reference Laboratories (NASDAQ:BRLI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bio-Reference Laboratories (NASDAQ:BRLI) Income Statement, Balance Sheet and Cash Flow Statement
Bio-Reference Laboratories (NASDAQ BRLI) Stock Chart for Friday, December, 15, 2017